Detection and characterization of viruses causing hand, foot and mouth disease from children in Seri Kembangan, Malaysia by Ling, B. P. et al.
* To whom all correspondence should be addressed.
E-mail: virologyprojects@gmail.com
Bacterial Nanoparticle As a Vaccine for Meningococcal Disease
Ahmad Nasser1, Maryam Zamirnasta1 and  Farid Azizi Jalilian2*
1Student Research Committee, School of Medicine, Ilam University of Medical Science, Iran.
2Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.
doi: http://dx.doi.org/10.13005/bbra/1294
(Received: 02 March 2014; accepted: 04 April 2014)
 Central nervous system infection, including viral or bacterial contamination is one of 
the main causes of disease and mortality. Kinds of vaccines to prevent infectious diseases are 
produced. These vaccines are usually produced by external or internal microbial components.
These components are usually made from a combination of proteins and carbohydrates, proteins 
or lipid. The bacteria is Types of pathogenic microbes that are considered capable of causing 
disease and potential use as antigens manufacturer to provider or transfer of vaccine. Bacteria 
contain  the various components such as a cell wall, outer membrane, lipopolysaccharides and 
the flagella, which all components has antigenic properties and stimulates the immune response. 
Utilize of outer membrane vesicles(OMV) is one of the newest and affordable cases.OMV as a 
nanometer proteoliposome particle  germinates through potential growth. OMV also increase 
the immunogenic protein antigen without adding the adjuvant. OMV product via two pathways: 
1) Recruiting of meningococcal bacteria that grow in a specific environment, 2) Transfer surface 
antigens to virus like particle in order to express surface antigen.Problem in the meningococcal 
bacteria presence of endotoxin and need a detoxified but in virus-like particle system does not 
have this issue because of endotoxin is absent, Instead there are limitation in gene transfer. 
One of the most studied bacteria that produces vesicles bacterium is Escherichia coli. Since 
the whole genome of E.coli bacteria could be detected and with genetic engineering of bacteria 
could be add antigens, and these antigens could be cloned. OMV expression  genes that induce 
immunity against cell surface antigens result to the immune response against diseases such as 
typhoid fever and meningococcal disease.
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 During its evolution, bacteria have learned 
how to compete eukaryotic cells, proliferation 
and survival in the environment or the host cell. 
Pathogenicity of these bacteria results from effects 
of the interaction these organisms with immune 
system. Secretion of Homo-serine lactone as 
extracellular protein, regulate the gene expression 
in bacterial populations1. However, this mechanism 
is highly efficient because these protein Exposure 
to rapid dilution and possible degradation by host 
cell proteases. OMV is an alternative cell to cell 
communication among bacteria has recently been 
proposed. OMV produced by the outer membrane 
of  gram negative bacteria can transmission of 
signal, transfer of DNA and proteins2. OMV has 
been used as a vector for vaccines and may also be 
used as drug carriers3. OMV produce may be due 
to a local increase in Periplasmic protein or lack 
of connection with the peptidoglycan layer4. For 
further OMV product, chemical and mechanical 
methods can be used to destroy Gram-negative 
bacteria5. Add or removing subunit proteins 
associated with the membrane could be formed 
due to the higher OMV formation that causes less 
stable membrane. One of important factor is the 
Tol-Pal system, a multi-protein complex that makes 
up the bridge between the outer membrane and the 
peptidoglycan6.
 OMV have been proposed as a different 
activities framework to do just one operation10 but 
In terms of their performance varies from external 
bodies such as the type 3 secretory system in the 
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bacterium such Pseudomonas aeruginosa11. Stress 
can trigger the release of large amounts of vesicles 
from the Pseudomonas aeruginosa, the synthesis of 
2-heptyl-3-hydroxy-4-quinolone (PQS) stimulation 
of omv production , this indicated that OMV 
production which is a regulatory factor rather 
Table 1. Crucial name of protein or gene expression of outer membrane vesicles 
Name of protein   Target References  
or Gene    
degP Removing it causes the more formation of outer membrane 
 vesicles  McBroom  AJ et al.[7]
egS Removing it causes the more formation of outer membrane 
 vesicles McBroom  AJ et al.[7]
fliC Removing it causes the decrease formation of outer membrane 
 vesicles Manabe  T et al.[8]
flgK Removing it causes the decrease formation of outer membrane 
 vesicles Manabe  T et al.[8]
rmpM Removing it causes the more formation of outer membrane van  de  Waterbeemd  
 vesicles B et al.[9]
Tol-Pal Removing each subunit causes the more formation of outer  van  de  Waterbeemd  
 membrane vesicles B et al.[9]
than to be a factor generated during stress12. PQS 
with hydrophobic properties can binds to the 
4×phosphate acyl chain from LPS, this interaction 
causes a flip-flop effect on the membrane and thus 
the outer layer surrounding the inner layer, when the 
area is large enough the membranes in response to 
this mismatch resulting to membrane budding and 
detachment the part of membrane and formation of 
OMV12. Due to separation and loss associated the 
outer membrane with the cell wall and underlying 
lipid, vesicles formation produced by the presence 
of lipid4. Geometric analysis of these vesicles with 
two-dimensional (2D) and Three-dimensional (3D) 
have shown that these vesicles are not stable in the 
size13. IN some bacteria shown that the OMV can 
transfer the fragment of DNA and plasmid10. DNA 
transfer with OMV in Ruminococcus bacteria has 
been found to help cause Cellulitis in strains that 
lacking these genes14.
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 OMV structure as a source of antigen 
presentation has advantage such as OMV surface 
antigen retains its physicochemical property. 
Using vesicles containing Escherichia coli ClyA 
and fusion antigen with ClyA result in different 
activities21. In The E.coli OMV is rich with ClyA, 
a bacterial hemolysin protein. ClyA is a toxin that 
causes a gap (pore) on the cell membrane and 
produced by invasive strain of Escherichia coli. 
To add other units including foreign antigens to 
OMV, they can be connected to the ClyA. It was 
also observed that the presence of ClyA merged 
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into OMV is dependent on oxidative status21, 22. 
OMV can affected with genetic engineering and 
with the aid of ClyA as the donor have different 
antigens on their surface. Other studies with 
recombinant Salmonella-containing OMV with 
Leishmania antigen shown the foreign antigen 
Pic. 1. TOl-Pal system and subunit” Presence of 
this subunit help the bacterial envelope 
stability by binding the outer membrane and 
cytoplasmic membrane to peptidoglycan
Pic. 2. View of outer membrane vesicle 
formation in the model with increasing 
units of peptidoglycan
Pic. 3. Types of nano-particles used for vaccine
was detected in the outer membrane of bacterial 
cell23. To produce and isolated vesicles, detergents 
such as deoxycolate or EDTA chelating element 
can used24 with destruction of the cell membrane, 
the vesicles is formed and release , Finally with 
the ultracentrifuge OMV can be absorbed into the 
precipitation of aluminum hydroxide.
OMV and Meningococcal
 Neisseria meningitidis serogroup B 
causes most of bacterial meningitis in adults25. Ivo 
Claassen et al. examining vaccines produced using 
genetically modified of two strains of serogroup 
B, this strains express class 1of outer membrane 
proteins that contain two proteins PorA and OMP. 
Finally, with the aid of deoxycolate the OMV 
extracted and aluminum phosphate as an adjuvant 
was used. It was found that the vaccine is safe for 
humans and can also cause an immune response in 
mice26-28. Capsular polysaccharide of Group B first 
option for vaccine, but unfortunately do not have an 
immunity29. After the culture in medium containing 
L - glutamate, L - cysteine, glucose, yeast extracts, 
incubated for 18 hours at a temperature of 36 ° C. 
Continuing with deoxycolate bacteria lysis and 
with the centrifuge carcass bacteria sedimented, in 
this case, OMV remains in the supernatant30. One 
problem with this method is the possible presence 
of endotoxin vaccine is that it examines with the 
extent Limulus methods. OMV vaccines combined 
with fivefold of Limulus lysate and will be kept 
for 45 minutes at 37 ° C, clotting Limulus lysate 
with lipid A indicative the presence of endotoxin. 
Activity these endotoxins are compared with 
Escherichia coli endotoxin31. Modern methods 
for removing endotoxins are use of mutants that 
are genetically have detoxified LPS, Also the 
mutant with more expression in the proteins, such 
as POrA can used32. Polysaccharide group B, N - 
acetyl Neuraminic acid that autoantigen. Today 
Polyvalent OMV vaccine for serogroups A, W, Y 
are generated and the first phase is over now33, 34.
OMV and its interaction with the immune 
system
 OMV such parent bacteria cell has 
interaction with the immune system and important 
factor to producing inflammation35. Outer membrane 
vesicle components including LPS and purines a 
part of complex heterogeneity that presented to 
pathogen-associated molecular patterns (PAMP) 
the first line of innate immune response. OMV 
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has more potential than LPS in stimulating the 
immune system, in the result nanoparticles play 
an essential role in the immune stimulation36. 
Using different OMV bacteria, immune response 
produce antibodies against antigenic complex in the 
vesicle37. Observed that OMV can be effectively 
induce humeral and mucosal immune response 
without requires the pathogens components18.
Discussion and conclusions
 Outer membrane vesicles are compounds 
that are released by the bacteria into the environment 
and transfer material such as DNA, proteins, 
toxins, etc. Producing OMV in bacterial culture 
and isolation this compound can be used as an 
inexpensive and effective vaccine. Finally with 
transfer other bacterial surface antigens into 
conjugated plasmid and integrated into bacteria can 
produced polyvalent vaccines. The benefits of this 
vaccine is cost, ease of preparation and processing, 
integrating multiple polyvalent vaccine a single 
vaccine and less need for booster. Other methods 
that have act similar outer membrane vesicles such: 
virus-like particles and hybrid particle systems can 
be used38.
  Disadvantages of hybrid Particle systems 
is the limit of mentioned antigens used , to produce 
this particles use polymers such as poly acetic 
acid, liposomes and simple lipid emulsion39. The 
disadvantages of using virus-like particles can 
limit the manipulation of these particles as a carrier 
(These particles have a limited ability to carry). 
The benefits of these particles referred to a simple 
biological structure. Due to the presence of low 
but steady release of vesicles in vivo and bacterial 
antigens, which now contain foreign antigens the 
stimulate the immune system over time and an 
acceptable level of antibodies will be present in 
the body for long time.
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